New York Lymphoma Rounds – POSTPONED

The New York Marriott East Side (click here for directions)
525 Lexington Avenue at East 49th St.
New York, NY 10017

TBA
6:00 PM – 8:30 PM

The New York Lymphoma Rounds program has been postponed due to the evolving situation with the novel coronavirus (COVID-19).  For updates, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation.

ACTIVITY CO-CHAIRS

Francesca Montanari, MD
Columbia University Medical Center

Andy Evens, DO, MSc, FACP
Rutgers Cancer Institute of New Jersey

Joshua Brody, MD
Icahn School of Medicine at Mount Sinai

This program is free for healthcare professionals; however, pre-registration is required. Food and refreshments will be provided for all registered participants.

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Sarah Quinlan, LRF, at squinlan@lymphoma.org.  Exhibit opportunities are also available, however, space is limited.

Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Sarah Quinlan (squinlan@lymphoma.org) at least one week before the program to confirm their attendance. Otherwise, an exhibit table will not be guaranteed.

ABOUT THE PROGRAM
The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

This is the final program in the 2019-2020 series.

New York Lymphoma Rounds Steering Committee

Columbia University Medical Center
Owen O’Connor, MD, PhD
Francesca Montanari, MD
Hackensack University Medical Center
Andre Goy, MD, MS
Icahn School of Medicine at Mount Sinai
Joshua Brody, MD
Memorial Sloan Kettering Cancer Center
Anthony Mato, MD, MSCE
David Straus, MD (chair)
NYU Langone Medical Center
Catherine Diefenbach, MD
Rutgers Cancer Institute of New Jersey
Joseph Bertino, MD
Andrew Evens, DO, MSc, FACP
Weill Cornell Medicine
Koen van Besien, MD, PhD
Ethel Cesarman, MD, PhD
Amy Chadburn, MD
Morton Coleman, MD
Yale University School of Medicine
Francine Foss, MD

Joint Providership Statement

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and the Lymphoma Research Foundation.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsors
Lymphoma Research Foundation and the University of Nebraska Medical Center, Center for Continuing Education

This activity is supported by educational grants from:

AbbVie, Inc., Acrotech Biopharma, LLC, AstraZeneca, BTG International, Inc., Celgene Corporation, Janssen Scientific Affairs, LLC and Pharmacyclics, LLC, an AbbVie Company, Kite Pharma, Inc., Novartis Pharmaceuticals Corporation, Seattle Genetics, Inc., TG Therapeutics, Inc. and Verastem Inc.